Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode
Sponsor: Janssen Pharmaceutica N.V., Belgium
Listed as NCT00216671, this PHASE4 trial focuses on Schizophrenia and remains completed. Sponsored by Janssen Pharmaceutica N.V., Belgium, it has been updated 8 times since 2005, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Pharmaceutica N.V., Belgium
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Bar-le-Duc, France , Bat Yam, Israel , Beaupuy, France , Chania, Greece , Clermont-Ferrand, France , Colmar, France , Copenhagen, Denmark , Danderyd, Sweden , Glostrup Municipality, Denmark and 21 more locations